{"organizations": [], "uuid": "9491b6e03812a77439604d60a1a259df49049e34", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.cnbc.com", "main_image": "", "site_section": "http://www.cnbc.com/id/10000027/page/6", "section_title": "Press Releases - CNBC", "url": "http://www.cnbc.com/2018/04/10/pr-newswire-technical-perspectives-on-medical-research-stocks--organovo-perkinelmer-precipio-and-thermo-fisher-scientific.html", "country": "US", "domain_rank": 767, "title": "Technical Perspectives on Medical Research Stocks -- Organovo, PerkinElmer, Precipio, and Thermo Fisher Scientific", "performance_score": 0, "site": "cnbc.com", "participants_count": 1, "title_full": "", "spam_score": 0.523, "site_type": "news", "published": "2018-04-10T14:15:00.000+03:00", "replies_count": 0, "uuid": "9491b6e03812a77439604d60a1a259df49049e34"}, "author": "cnbc.com", "url": "http://www.cnbc.com/2018/04/10/pr-newswire-technical-perspectives-on-medical-research-stocks--organovo-perkinelmer-precipio-and-thermo-fisher-scientific.html", "ord_in_thread": 0, "title": "Technical Perspectives on Medical Research Stocks -- Organovo, PerkinElmer, Precipio, and Thermo Fisher Scientific", "locations": [], "entities": {"persons": [], "locations": [{"name": "san diego", "sentiment": "none"}, {"name": "california", "sentiment": "none"}], "organizations": [{"name": "thermo fisher scientific new york", "sentiment": "negative"}, {"name": "perkinelmer", "sentiment": "negative"}, {"name": "precipio inc.", "sentiment": "none"}, {"name": "company", "sentiment": "none"}, {"name": "wallstequities.com", "sentiment": "none"}, {"name": "organovo holdings inc.", "sentiment": "none"}, {"name": "tmo", "sentiment": "none"}, {"name": "nyse", "sentiment": "none"}, {"name": "healthcare", "sentiment": "none"}, {"name": "thermo fisher scientific inc.", "sentiment": "none"}, {"name": "onvo", "sentiment": "none"}, {"name": "perkinelmer inc.", "sentiment": "none"}, {"name": "pki", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "NEW YORK, April 10, 2018 /PRNewswire/ --\nWallStEquities.com strives to bring the best free research to the investment community. Today we are offering reports on ONVO, PKI, PRPO, and TMO which can be accessed for free by signing up to www.wallstequities.com/registration . WallStEquities.com reviews Organovo Holdings Inc. (NASDAQ: ONVO), PerkinElmer Inc. (NYSE: PKI), Precipio Inc. (NASDAQ: PRPO), and Thermo Fisher Scientific Inc. (NYSE: TMO). Medical Laboratories and Research companies focus on performing various tests on patients that give them information on patients' health. As a whole, they tend to offer higher dividend yields than the wider Healthcare sector. All you have to do is sign up today for this free limited time offer by clicking the link below.\nwww.wallstequities.com/registration\nOrganovo Holdings\nShares in San Diego, California headquartered Organovo Holdings Inc. rose 2.94%, ending Monday's trading session at $0.99. The stock recorded a trading volume of 1.05 million shares, which was higher than its three months average volume of 989,230 shares. The Company's shares are trading 12.69% below their 50-day moving average. Moreover, shares of Organovo, which designs and creates functional and 3D human tissues for use in medical research and therapeutic applications, have a Relative Strength Index (RSI) of 40.45.\nOn March 26 th , 2018, Organovo announced that its wholly owned subsidiary, Samsara Sciences, Inc. (\"Samsara\"), a provider of highly specialized human liver cells, entered a non-exclusive global supply agreement with Lonza Bioscience Solutions (\"Lonza\"). Under the terms of the agreement, Lonza will market human cell products from Samsara for further distribution to its customers. Get the full research report on ONVO for free by clicking below at: www.wallstequities.com/registration/?symbol=ONVO\nPerkinElmer\nWaltham, Massachusetts headquartered PerkinElmer Inc.'s stock climbed 1.30%, closing the day at $74.15 with a total trading volume of 530,137 shares. The Company's shares have advanced 28.18% over the past year. The stock is trading 3.16% above its 200-day moving average. Additionally, shares of PerkinElmer, which provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide, have an RSI of 44.53.\nOn April 06 th , 2018, PerkinElmer announced that it will release its Q1 2018 results on April 30 th , 2018, after market close. The Company will also host a conference call the same day at 5:00 p.m. ET to discuss these results. Robert Friel, Chairman and CEO, and Andy Wilson, Senior Vice President and CFO, will host the conference call. Access the free research report on PKI now by signing up at: www.wallstequities.com/registration/?symbol=PKI\nPrecipio\nOn Monday, shares in New Haven, Connecticut-based Precipio Inc. recorded a trading volume of 506,014 shares. The stock ended the day 6.41% higher at $0.46. The Company's shares are trading below their 50-day moving average by 35.60%. Furthermore, shares of Precipio, which provides platform to eradicate the problem of misdiagnosis within academic institutions, have an RSI of 40.20.\nOn March 13 th , 2018, Precipio announced that it has settled its lawsuit with Crede Capital Group LLC, restructuring the final substantial liability of legacy payables inherited as part of the merger with Transgenomic in June 2017. These liabilities have been reduced from approximately $19 million at the merger to approximately $7 million (a reduction of close to 65%). Are you already registered with Wall St. Equities? Do so now for free, and get the report on PRPO at: www.wallstequities.com/registration/?symbol=PRPO\nThermo Fisher Scientific\nWaltham, Massachusetts headquartered Thermo Fisher Scientific Inc.'s stock rose 1.94%, finishing yesterday's session at $209.55 with a total trading volume of 1.40 million shares. The Company's shares have advanced 3.54% in the previous three months and 37.01% over the past year. The stock is trading above its 200-day moving average by 8.25%. Additionally, shares of the Company, which provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide, have an RSI of 50.93.\nOn April 03 rd , 2018, Thermo Fisher Scientific announced that it will release its financial results for Q1 2018 before the market opens on April 25 th , 2018 and will hold a conference call on the same day at 8:30 a.m. EDT. The call may be accessed live under the \"Investors\" section of the Company's website. Aspiring Member, please take a moment to register below for your free research report on TMO at: www.wallstequities.com/registration/?symbol=TMO\n--\nWall St. Equities :\nWall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.\nWSE has not been compensated; directly or indirectly; for producing or publishing this document.\nPRESS RELEASE PROCEDURES :\nThe non-sponsored content contained herein has been prepared by a writer (the \"Author\") and is fact checked and reviewed by a third-party research service company (the \"Reviewer\") represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com . Rohit Tuli, a CFAÂ® charterholder (the \"Sponsor\"), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.\nNO WARRANTY\nWSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.\nNOT AN OFFERING\nThis document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/\nCONTACT\nFor any questions, inquiries, or comments reach out to us directly. If you're a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:\nEmail: info@wallstequities.com\nPhone number: +21-32-044-483\nOffice Address: 1 Scotts Road #24-10, Shaw Center Singapore 228\nCFAÂ® and Chartered Financial AnalystÂ® are registered trademarks owned by CFA Institute.\nView original content: http://www.prnewswire.com/news-releases/technical-perspectives-on-medical-research-stocks----organovo-perkinelmer-precipio-and-thermo-fisher-scientific-300627039.html\nSOURCE Wall St. Equities", "external_links": ["http://www.wallstequities.com/registration/?symbol=TMO", "http://www.wallstequities.com/registration/?symbol=PRPO", "https://wallstequities.com/legal-disclaimer/", "http://www.wallstequities.com/registration/?symbol=PKI", "http://www.wallstequities.com/registration/?symbol=ONVO", "http://www.prnewswire.com/news-releases/technical-perspectives-on-medical-research-stocks----organovo-perkinelmer-precipio-and-thermo-fisher-scientific-300627039.html", "http://www.wallstequities.com/registration"], "published": "2018-04-10T14:15:00.000+03:00", "crawled": "2018-04-10T17:10:30.006+03:00", "highlightTitle": ""}